In Cell this week: integrated genomic analysis of adult soft tissue sarcoma, positive selection has greater role in cancer than negative selection, and more.
The WIN Consortium's Catherine Bresson discusses the association's approach for treating cancer patients at the Independent.
The researchers found that most advanced EGFR-mutant lung cancer patients harbored changes in an average of two to three other oncogenes.
A pair of papers point to potential gut microbial contributions to checkpoint blockade immunotherapy response in individuals with lung, kidney, or skin cancer.
The companies plan to develop Thermo's Oncomine Dx Target Test as a companion diagnostic for Blueprint's BLU-667 to identify RET fusions in NSCLC patients.
A Mount Sinai team performed targeted sequencing on non-small cell lung cancer samples to find mutations with clinical implications.
The researchers combined different proteomic methods to explore the activity of the ALK inhibitor ceritinib and identify potential combination therapies.
The NGS-based test, which was approved by the FDA in June, will be now available to the insurers' members, who have non-small cell lung cancer, in four states.
The lung cancer institute will work with Inivata to study the use of ctDNA testing in patients with early lung cancer after surgery.
Gencurix's assay can be used to select which non-small cell lung cancer patients will respond to tyrosine kinase inhibitors.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.